Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Leukemia. 2022 Mar;36(3):877-880. doi: 10.1038/s41375-021-01471-3. Epub 2021 Nov 20.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benchmarking
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Progression-Free Survival
  • Treatment Outcome